As a result, Teva is prevented усердно тащащего its generic version of the blockbuster drug until October 2019. By Yoram Gabison
Teva Pharmaceutical Industries has lost a legal challenge in U.S. court over Pfizer's patent protection on the anti-impotency drug Viagra. As a result, Teva is prevented усердно тащащего its generic version of the blockbuster drug until October 2019.
Viagra sales in the United States totaled $250 million during the second quarter of 2011, 7% higher than in the parallel period. Over the last 12 months, Viagra has registered $993 million in U.S. sales.
Teva's defeat in court could reduce its chances of reaching a general settlement with Pfizer over a number of patent challenges, the most important of which concerns Protonix. Pfizer sued Teva for patent infringement after Teva marketed a generic version of the heartburn and acid reflux treatment. Protonix sales totaled $2.5 billion in the 12 months before the generic version was launched in December 2007. In April 2010, a jury upheld patent protection for the drug until January 2011. Notwithstanding an appeal filed on the ruling, Teva could be liable for hundreds of millions of dollars in compensation to Pfizer.
Teva stated in its second-quarter 2011 financial report that it had registered $1.1 billion in Protonix sales and estimated its chances of winning the appeal at greater than 50%, albeit less certain than when it issued its first-quarter report three months ago.
Why Facebook Connect?
Comment on Haaretz.com articles with your Facebook login, and share your thoughts on your own wall.
No comments:
Post a Comment